Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sage Therapeutic Com (NQ: SAGE ) 7.220 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sage Therapeutic Com < Previous 1 2 ... 5 6 7 8 9 10 11 12 Next > Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder May 02, 2022 Via Benzinga The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More May 02, 2022 Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... Via Benzinga Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) May 02, 2022 From Sage Therapeutics, Inc. Via Business Wire Expert Ratings For Sage Therapeutics March 31, 2022 Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter: Via Benzinga Where Sage Therapeutics Stands With Analysts December 20, 2021 Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE... Via Benzinga Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know April 21, 2022 Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. Via Benzinga Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022 April 19, 2022 From Sage Therapeutics, Inc. Via Business Wire The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel April 05, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight April 03, 2022 Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday April 01, 2022 Good morning, investor! It's the last trading day of the week and that means it's time to get into the pre-market stock movers for Friday! Via InvestorPlace Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease April 01, 2022 From Sage Therapeutics, Inc. Via Business Wire Sage Therapeutics to Present at 2022 Stifel CNS Days March 22, 2022 From Sage Therapeutics, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022 March 31, 2022 Upgrades Via Benzinga Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease March 15, 2022 From Sage Therapeutics, Inc. Via Business Wire Expert Ratings For Sage Therapeutics February 25, 2022 Over the past 3 months, 4 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and... Via Benzinga The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company February 24, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... Via Benzinga Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress February 24, 2022 From Sage Therapeutics, Inc. Via Business Wire The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow February 20, 2022 Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... Via Benzinga Why A Biogen-Sage Drug Flopped — And Could Still Be Approved February 16, 2022 The companies tested a combination of zuranolone and depression drugs. Via Investor's Business Daily Stocks That Hit 52-Week Lows On Thursday February 17, 2022 On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company... Via Benzinga 56 Biggest Movers From Yesterday February 17, 2022 Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead... Via Benzinga 40 Stocks Moving In Wednesday's Mid-Day Session February 16, 2022 Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral... Via Benzinga Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study February 16, 2022 Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday February 16, 2022 We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday! Via InvestorPlace Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD February 16, 2022 From Sage Therapeutics, Inc. Via Business Wire Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022 February 10, 2022 From Sage Therapeutics, Inc. Via Business Wire New Psychedelics ETF Launches On NYSE Arca February 02, 2022 Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)... Via Benzinga Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 January 04, 2022 From Sage Therapeutics, Inc. Via Business Wire Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S. December 28, 2021 Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... Via Benzinga 5 Value Stocks In The Healthcare Sector December 27, 2021 Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... Via Benzinga < Previous 1 2 ... 5 6 7 8 9 10 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.